Premium
Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I–II study
Author(s) -
Greenberg Bernard R.,
Reynolds Ralph D.,
Charron Carolyn B.,
Squillace Kathleen M.,
Lessin Lawrence S.,
Case Delvyn C.,
Gams Richard A.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930315)71:6<1989::aid-cncr2820710611>3.0.co;2-t
Subject(s) - idarubicin , medicine , myelodysplastic syndromes , anthracycline , toxicity , oral administration , chemotherapy , surgery , bone marrow , complete remission , cancer , breast cancer
Background . Idarubicin, a new anthracycline analogue, is available in an oral preparation, and responses have been observed using relatively aggressive therapy in patients with myelodysplastic syndromes (MDS). The authors studied whether a chronic low‐dose schedule would be effective but less myelotoxic. Methods . Forty‐two patients with MDS received daily low‐dose oral idarubicin in 5‐week courses that included 3 weeks of treatment, followed by a 2‐week rest period. Doses were escalated when possible after the second course, and each patient was to receive six courses. Results . Only one partial response was observed. Although no patient had fatal bone marrow toxicity, only eight patients received the full six courses, primarily because of myelosuppression. Conclusions . This schedule of oral idarubicin is relatively safe but produces fewer responses than are reported with the high‐dose pulse regimens.